{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:34Z","timestamp":1792167514821,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,21]]},"DOI":"10.7759\/cureus.29413","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T17:53:58Z","timestamp":1663782838000},"source":"Crossref","is-referenced-by-count":1,"title":["Current Status of Dapagliflozin in Congestive Heart Failure"],"prefix":"10.7759","author":[{"given":"Gopal","family":"Palandurkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese G","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017, 3:7-11. 10.15420\/cfr.2016:25:2","journal-title":"Card Fail Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0815-3","article-title":"Cost-of-illness studies in heart failure: a systematic review 2004-2016","volume":"18","author":"Lesyuk W","year":"2018","unstructured":"Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004-2016. BMC Cardiovasc Disord. 2018, 18:74. 10.1186\/s12872-018-0815-3","journal-title":"BMC Cardiovasc Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12363","article-title":"Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach","volume":"6","author":"Gallagher AM","year":"2019","unstructured":"Gallagher AM, Lucas R, Cowie MR. Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach. ESC Heart Fail. 2019, 6:3-9. 10.1002\/ehf2.12363","journal-title":"ESC Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12369","article-title":"Self-reported health and quality of life outcomes of heart failure patients in the aftermath of a national economic crisis: a cross-sectional study","volume":"6","author":"Ketilsdottir A","year":"2019","unstructured":"Ketilsdottir A, Ingadottir B, Jaarsma T. Self-reported health and quality of life outcomes of heart failure patients in the aftermath of a national economic crisis: a cross-sectional study. ESC Heart Fail. 2019, 6:111-21. 10.1002\/ehf2.12369","journal-title":"ESC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian B","year":"2016","unstructured":"Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016, 13:368-78. 10.1038\/nrcardio.2016.25","journal-title":"Nat Rev Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2016.07.001","article-title":"Understanding heart failure","volume":"13","author":"Mazurek JA","year":"2017","unstructured":"Mazurek JA, Jessup M. Understanding heart failure. Heart Fail Clin. 2017, 13:1-19. 10.1016\/j.hfc.2016.07.001","journal-title":"Heart Fail Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00310-6","article-title":"Ketone bodies for the starving heart","volume":"2","author":"Schulze PC","year":"2020","unstructured":"Schulze PC, Wu JM. Ketone bodies for the starving heart. Nat Metab. 2020, 2:1183-5. 10.1038\/s42255-020-00310-6","journal-title":"Nat Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: The Framingham study","volume":"34","author":"Kannel WB","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974, 34:29-34. 10.1016\/0002-9149(74)90089-7","journal-title":"Am J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Fern\u00e1ndez-Balsells MM","year":"2017","unstructured":"Fern\u00e1ndez-Balsells MM, Sojo-Vega L, Ricart-Engel W. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:2098. 10.1056\/NEJMc1712572","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:e240-327. 10.1161\/CIR.0b013e31829e8776","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.10.030","article-title":"Risk factors for heart failure in the community: differences by age and ejection fraction","volume":"133","author":"Chamberlain AM","year":"2020","unstructured":"Chamberlain AM, Boyd CM, Manemann SM, et al.. Risk factors for heart failure in the community: differences by age and ejection fraction. Am J Med. 2020, 133:e237-48. 10.1016\/j.amjmed.2019.10.030","journal-title":"Am J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15141","article-title":"Evolution of a geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction","volume":"65","author":"Upadhya B","year":"2017","unstructured":"Upadhya B, Pisani B, Kitzman DW. Evolution of a geriatric syndrome: pathophysiology and treatment of heart failure with preserved ejection fraction. J Am Geriatr Soc. 2017, 65:2431-40. 10.1111\/jgs.15141","journal-title":"J Am Geriatr Soc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.307547","article-title":"Cardiovascular disease in women: clinical perspectives","volume":"118","author":"Garcia M","year":"2016","unstructured":"Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016, 118:1273-93. 10.1161\/CIRCRESAHA.116.307547","journal-title":"Circ Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.57","article-title":"Clinical features, management, and short- and long-term outcomes of patients with acute decompensated heart failure: phase I results of the HEARTS database","volume":"16","author":"AlHabib KF","year":"2014","unstructured":"AlHabib KF, Elasfar AA, Alfaleh H, et al.. Clinical features, management, and short- and long-term outcomes of patients with acute decompensated heart failure: phase I results of the HEARTS database. Eur J Heart Fail. 2014, 16:461-9. 10.1002\/ejhf.57","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme\u2014a survey on the quality of care among patients with heart failure in Europe: part 1: patient characteristics and diagnosis","volume":"24","author":"Cleland JGF","year":"2003","unstructured":"Cleland JGF, Swedberg K, Follath F, et al.. The EuroHeart Failure survey programme\u2014a survey on the quality of care among patients with heart failure in Europe: part 1: patient characteristics and diagnosis. Eur Heart J. 2003, 24:442-63. 10.1016\/S0195-668X(02)00823-0","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni AP","year":"2013","unstructured":"Maggioni AP, Dahlstr\u00f6m U, Filippatos G, et al.. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013, 15:808-17. 10.1093\/eurjhf\/hft050","journal-title":"Eur J Heart Fail"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl193","article-title":"EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population","volume":"27","author":"Nieminen MS","year":"2006","unstructured":"Nieminen MS, Brutsaert D, Dickstein K, et al.. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006, 27:2725-36. 10.1093\/eurheartj\/ehl193","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.000161","article-title":"Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry","volume":"6","author":"Tavazzi L","year":"2013","unstructured":"Tavazzi L, Senni M, Metra M, et al.. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013, 6:473-81. 10.1161\/CIRCHEARTFAILURE.112.000161","journal-title":"Circ Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000035","article-title":"Death by oxymoron? The enigma of heart failure with preserved ejection fraction","volume":"8","author":"Beattie JM","year":"2014","unstructured":"Beattie JM. Death by oxymoron? The enigma of heart failure with preserved ejection fraction. Curr Opin Support Palliat Care. 2014, 8:1-3. 10.1097\/SPC.0000000000000035","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-5411.2013.04.011","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Rigolli M","year":"2013","unstructured":"Rigolli M, Whalley GA. Heart failure with preserved ejection fraction. J Geriatr Cardiol. 2013, 10:369-76. 10.3969\/j.issn.1671-5411.2013.04.011","journal-title":"J Geriatr Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer MA","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019, 124:1598-617. 10.1161\/CIRCRESAHA.119.313572","journal-title":"Circ Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1594","article-title":"Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis","volume":"21","author":"Jones NR","year":"2019","unstructured":"Jones NR, Roalfe AK, Adoki I, Hobbs FD, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019, 21:1306-25. 10.1002\/ejhf.1594","journal-title":"Eur J Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland","volume":"19","author":"Mamas MA","year":"2017","unstructured":"Mamas MA, Sperrin M, Watson MC, et al.. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017, 19:1095-104. 10.1002\/ejhf.822","journal-title":"Eur J Heart Fail"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1210","article-title":"Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan","volume":"20","author":"Nagai T","year":"2018","unstructured":"Nagai T, Sundaram V, Shoaib A, et al.. Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. Eur J Heart Fail. 2018, 20:1179-90. 10.1002\/ejhf.1210","journal-title":"Eur J Heart Fail"},{"key":"ref28","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION. (2014). Accessed. August 5, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202293s020lbl.pdf."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-021-00503-8","article-title":"Dapagliflozin: a review in symptomatic heart failure with reduced ejection fraction","volume":"21","author":"Blair HA","year":"2021","unstructured":"Blair HA. Dapagliflozin: a review in symptomatic heart failure with reduced ejection fraction. Am J Cardiovasc Drugs. 2021, 21:701-10. 10.1007\/s40256-021-00503-8","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes","volume":"79","author":"Dhillon S","year":"2019","unstructured":"Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019, 79:1135-46. 10.1007\/s40265-019-01148-3","journal-title":"Drugs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0324-3","article-title":"Dapagliflozin: a review of its use in patients with type 2 diabetes","volume":"74","author":"Plosker GL","year":"2014","unstructured":"Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014, 74:2191-209. 10.1007\/s40265-014-0324-3","journal-title":"Drugs"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01213-x","article-title":"Dapagliflozin: a review in type 1 diabetes","volume":"79","author":"Paik J","year":"2019","unstructured":"Paik J, Blair HA. Dapagliflozin: a review in type 1 diabetes. Drugs. 2019, 79:1877-84. 10.1007\/s40265-019-01213-x","journal-title":"Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato ET","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, et al.. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019, 139:2528-36. 10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod MN","year":"2020","unstructured":"Kosiborod MN, Jhund PS, Docherty KF, et al.. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020, 141:90-9. 10.1161\/CIRCULATIONAHA.119.044138","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: the DEFINE-HF trial","volume":"140","author":"Nassif ME","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, et al.. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: the DEFINE-HF trial. Circulation. 2019, 140:1463-76. 10.1161\/CIRCULATIONAHA.119.042929","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.10.071","article-title":"Efficacy and safety of dapagliflozin in acute heart failure: rationale and design of the DICTATE-AHF trial","volume":"232","author":"Cox ZL","year":"2021","unstructured":"Cox ZL, Collins SP, Aaron M, et al.. Efficacy and safety of dapagliflozin in acute heart failure: rationale and design of the DICTATE-AHF trial. Am Heart J. 2021, 232:116-24. 10.1016\/j.ahj.2020.10.071","journal-title":"Am Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon SD","year":"2021","unstructured":"Solomon SD, de Boer RA, DeMets D, et al.. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021, 23:1217-25. 10.1002\/ejhf.2249","journal-title":"Eur J Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, et al.. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021, 9:22-31. 10.1016\/S2213-8587(20)30369-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, DeMets DL, Inzucchi SE, et al.. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019, 21:665-75. 10.1002\/ejhf.1432","journal-title":"Eur J Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/112818-current-status-of-dapagliflozin-in-congestive-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:26Z","timestamp":1707507566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/112818-current-status-of-dapagliflozin-in-congestive-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.29413","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}